161 related articles for article (PubMed ID: 6110217)
1. Differential effects of amphetamine and neuroleptics on negative vs. positive symptoms in schizophrenia.
Angrist B; Rotrosen J; Gershon S
Psychopharmacology (Berl); 1980; 72(1):17-9. PubMed ID: 6110217
[TBL] [Abstract][Full Text] [Related]
2. Empirical evaluation of the factorial structure of clinical symptoms in schizophrenia: effects of typical neuroleptics on the brief psychiatric rating scale.
Harvey PD; Davidson M; White L; Keefe RS; Hirschowitz J; Mohs RC; Davis KL
Biol Psychiatry; 1996 Oct; 40(8):755-60. PubMed ID: 8894068
[TBL] [Abstract][Full Text] [Related]
3. Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia.
Ascher-Svanum H; Stensland M; Zhao Z; Kinon BJ
BMC Psychiatry; 2005 Jan; 5():3. PubMed ID: 15649317
[TBL] [Abstract][Full Text] [Related]
4. The relationship of clozapine and haloperidol treatment response to prefrontal, hippocampal, and caudate brain volumes.
Arango C; Breier A; McMahon R; Carpenter WT; Buchanan RW
Am J Psychiatry; 2003 Aug; 160(8):1421-7. PubMed ID: 12900303
[TBL] [Abstract][Full Text] [Related]
5. Lack of behavioral supersensitivity to d-amphetamine after pimozide withdrawal. A trial with schizophrenic patients.
van Kammen DP; Docherty JP; Marder SR; Schulz SC; Bunney WE
Arch Gen Psychiatry; 1980 Mar; 37(3):287-90. PubMed ID: 6102456
[TBL] [Abstract][Full Text] [Related]
6. Blunted change in cerebral glucose utilization after haloperidol treatment in schizophrenic patients with prominent negative symptoms.
Wolkin A; Sanfilipo M; Duncan E; Angrist B; Wolf AP; Cooper TB; Brodie JD; Laska E; Rotrosen JP
Am J Psychiatry; 1996 Mar; 153(3):346-54. PubMed ID: 8610821
[TBL] [Abstract][Full Text] [Related]
7. Responses to apomorphine, amphetamine, and neuroleptics in schizophrenic subjects.
Angrist B; Rotrosen J; Gershon S
Psychopharmacology (Berl); 1980 Jan; 67(1):31-8. PubMed ID: 6102776
[TBL] [Abstract][Full Text] [Related]
8. Schizophrenia model of elevated D2(High) receptors: haloperidol reverses the amphetamine-induced elevation in dopamine D2(High).
Seeman P
Schizophr Res; 2009 Apr; 109(1-3):191-2. PubMed ID: 19171464
[No Abstract] [Full Text] [Related]
9. Nonstriatal dopaminergic neurons: Section X. Morphine, amphetamine, and noncataleptogenic neuroleptics: Introduction: morphine, amphetamine, and noncataleptogenic neuroleptics.
Costa E
Adv Biochem Psychopharmacol; 1977; 16():557-63. PubMed ID: 18900
[No Abstract] [Full Text] [Related]
10. Neuroendocrine serotonergic and dopaminergic responsivity in male schizophrenic patients during treatment with neuroleptics and after switch to risperidone.
Markianos M; Hatzimanolis J; Lykouras L
Psychopharmacology (Berl); 2001 Aug; 157(1):55-9. PubMed ID: 11512043
[TBL] [Abstract][Full Text] [Related]
11. [Incidence of the deficit form in refractory schizophrenia].
Samuelian JC
Encephale; 1996 Jun; 22 Spec No 2():19-23. PubMed ID: 8767037
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of negative symptoms in outpatients with schizophrenia spectrum disorders treated with antipsychotics in routine clinical practice: findings from the CLAMORS study.
Bobes J; Arango C; Garcia-Garcia M; Rejas J;
J Clin Psychiatry; 2010 Mar; 71(3):280-6. PubMed ID: 19895779
[TBL] [Abstract][Full Text] [Related]
13. The effect of neuroleptics and other psychotropic drugs on negative symptoms in schizophrenia.
Meltzer HY; Sommers AA; Luchins DJ
J Clin Psychopharmacol; 1986 Dec; 6(6):329-38. PubMed ID: 2879856
[TBL] [Abstract][Full Text] [Related]
14. Are antagonists of dopamine D1 receptors drugs that attenuate both positive and negative symptoms of schizophrenia? A pilot study in Java monkeys.
Ellenbroek BA; Willemen AP; Cools AR
Neuropsychopharmacology; 1989 Sep; 2(3):191-9. PubMed ID: 2571339
[TBL] [Abstract][Full Text] [Related]
15. Novel pharmacological approaches to the treatment of schizophrenia.
Fink-Jensen A
Dan Med Bull; 2000 Jun; 47(3):151-67. PubMed ID: 10913983
[TBL] [Abstract][Full Text] [Related]
16. The relationship between negative symptoms of schizophrenia and extrapyramidal side effects with haloperidol and olanzapine.
Allan ER; Sison CE; Alpert M; Connolly B; Crichton J
Psychopharmacol Bull; 1998; 34(1):71-4. PubMed ID: 9564201
[TBL] [Abstract][Full Text] [Related]
17. The effects of Ginkgo biloba extract added to haloperidol on peripheral T cell subsets in drug-free schizophrenia: a double-blind, placebo-controlled trial.
Zhang XY; Zhou DF; Cao LY; Wu GY
Psychopharmacology (Berl); 2006 Sep; 188(1):12-7. PubMed ID: 16906395
[TBL] [Abstract][Full Text] [Related]
18. Depression in schizophrenia: comparison of first- and second-generation antipsychotic drugs.
Mauri MC; Moliterno D; Rossattini M; Colasanti A
Schizophr Res; 2008 Feb; 99(1-3):7-12. PubMed ID: 18055177
[TBL] [Abstract][Full Text] [Related]
19. Negative signs and symptoms secondary to antipsychotics: a double-blind, randomized trial of a single dose of placebo, haloperidol, and risperidone in healthy volunteers.
Artaloytia JF; Arango C; Lahti A; Sanz J; Pascual A; Cubero P; Prieto D; Palomo T
Am J Psychiatry; 2006 Mar; 163(3):488-93. PubMed ID: 16513871
[TBL] [Abstract][Full Text] [Related]
20. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group.
Small JG; Hirsch SR; Arvanitis LA; Miller BG; Link CG
Arch Gen Psychiatry; 1997 Jun; 54(6):549-57. PubMed ID: 9193196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
